Lakefront Biotherapeutics NV current report, Q2 FY2025

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of May 2025. The filing, dated May 13, 2025, serves to incorporate by reference a press release (Exhibit 99.1) issued on the same date. The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Form 20-F.

Financial Metrics

The filing text provided does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document. The filing acts solely as a conduit for the attached press release, the content of which is not included in the source text.

Material Changes

No material changes versus prior periods are described in the provided text. The document references a press release but does not summarize its contents regarding operational or financial changes.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, guidance, outlook, risks, contingencies, or details on unusual items. It notes that quotes from Jérôme Contamine and Henry Gosebruch in the attached press release are not incorporated by reference into the company's Registration Statements on Form S-8.

Key Facts for Investor Verification

  • Entity Discrepancy: The metadata lists "Lakefront Biotherapeutics NV," but the filing is explicitly for "Galapagos NV." Investors must verify the correct entity.
  • Missing Content: The core information (the press release) is referenced as Exhibit 99.1 but is not included in the provided text. Investors must locate the full press release to understand the material event.
  • Exclusion of Quotes: Specific quotes from executives in the press release are excluded from incorporation into Form S-8 registration statements.
  • No Financial Data: This specific filing contains no numerical financial metrics.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.